<DOC>
	<DOCNO>NCT03019276</DOCNO>
	<brief_summary>To study pharmacokinetic characteristic TQ-B3101 human body , recommend reasonable regimen subsequent research .</brief_summary>
	<brief_title>A Phase I Study TQ-B3101 Tolerance Pharmacokinetics</brief_title>
	<detailed_description />
	<criteria>Histological documentation Advanced solid tumor Lack standard treatment treatment failure 1870years , ECOG PS:01 , Life expectancy 3 month Main organ function normal Women childbearing potential agree use utilize adequate method contraception ( intrauterine device，contraceptive condom ) throughout treatment least 6 month study stopped；the result serum urine pregnancy test negative within 7 day prior study enrollment，and patient require nonlactating；Man participant agree use utilize adequate method contraception throughout treatment least 6 month study stop Patients participate study voluntarily sign informed consent Patients treatment failure ALK/ROS1 inhibitor Patients antiteratment , radiotherapy surgery within 4 week Patients participate anticancer drug clinical trial within 4 week ALK/ROS1 inhibitor within 1 week Blood pressure unable control ( systolic pressure &gt; 140 mmHg，diastolic pressure &gt; 90 mmHg ) . Patients Grade 1 high myocardial ischemia , myocardial infarction malignant arrhythmia ( include QT≥470ms ) Patients nonhealing wound fracture Patients drug abuse history unable get rid Patients mental disorder History immunodeficiency Patients concomitant disease could seriously endanger safety could affect completion study accord investigator ' judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>